Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Mar;31(2):151-159.
doi: 10.1097/PGP.0b013e318226b376.

PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia

Kimberly H Allison  1 , Kristen Upson, Susan D Reed, Carolyn D Jordan, Katherine M Newton, Jennifer Doherty, Elizabeth M Swisher, Rochelle L Garcia
Affiliations
Case Reports

PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia

Kimberly H Allison et al. Int J Gynecol Pathol. 2012 Mar.

Abstract

Immunohistochemical markers to assist in the diagnosis and classification of hyperplastic endometrial epithelial proliferations would be of diagnostic use. To examine the possible use of PAX2 as a marker of hyperplastic endometrium, cases of normal endometrium, simple and complex hyperplasia without atypia, atypical hyperplasia, and International Federation of Gynecology and Obstetrics (FIGO) grade 1 endometrioid carcinomas were stained for PAX2. Two hundred and six endometrial samples were available for interpretation of PAX2 staining. The percentage of cases with complete PAX2 loss (0% of cells staining) increased with increasing severity of hyperplasia: 0% of normal proliferative and secretory endometrium (n=28), 17.4% of simple hyperplasia (n=23), 59.0% of complex hyperplasia (n=83), 74.1% of atypical hyperplasia (n=54), and 73.3% of FIGO grade 1 endometrioid cancers (n=15). Partial loss of PAX2 expression did occur in normal endometrium (17.9%) but in smaller proportions of tissue and was less frequent than in simple hyperplasia (47.8% with partial loss), complex hyperplasia (32.5%), atypical hyperplasia (22.2%), and FIGO grade 1 carcinomas (20.0%). Uniform PAX2 expression was rare in complex (8.4%) and atypical hyperplasia (3.7%) and carcinoma (6.7%). When evaluating loss of PAX2 in histologically normal endometrium adjacent to lesional endometrium in a given case, statistically significant differences in staining were observed for simple hyperplasia (P=0.011), complex hyperplasia (P<0.001), atypical hyperplasia (P<0.001), and FIGO grade 1 endometrioid cancer (P=0.003). In summary, PAX2 loss seems to occur early in the development of endometrial precancers and may prove useful in some settings as a diagnostic marker in determining normal endometrium from complex and atypical hyperplasia and low-grade carcinomas. However, it is not useful in distinguishing between these diagnostic categories.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percent glandular cells with PAX2 staining.
Figure 2
Figure 2
Strong and uniform nuclear PAX2 expression was characteristic of normal proliferative endometrium (A) and secretory endometrium (B). Occasional partial loss of PAX2 expression did occur in background histologically normal endometrium (C). Complete loss of nuclear PAX2 expression was much more characteristic of complex hyperplasia (D), atypical hyperplasia (E) and FIGO grade 1 endometrioid carcinoma (F).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Beutler HK, Dockerty MB, Randall LM. Precancerous lesions of the endometrium. Am J Obstet Gynecol. 1963;86:433–43. - PubMed
    1. Campbell PE, Barter RA. The significance of a typical endometrial hyperplasia. J Obstet Gynaecol Br Commonw. 1961;68:668–72. - PubMed
    1. Gore H, Hertig AT. Carcinoma in situ of the endometrium. Am J Obstet Gynecol. 1966;94(1):134–55. - PubMed
    1. Gusberg SB, Kaplan AL. Precursors of Corpus Cancer. Iv. Adenomatous Hyperplasia as Stage O Carcinoma of the Endometrium. Am J Obstet Gynecol. 1963;87:662–78. - PubMed
    1. Hendrickson MKR. Surgical Pathology of the Uterine Corpus Vol. WB Saunders Co.; Philadelphia: 1980.

Publication types

LinkOut - more resources